Interpregnancy Risk Stratification for Maternal Health

Abstract

Interpregnancy risk stratification is an evolving and clinically significant approach aimed at optimizing maternal health outcomes by identifying and managing women at increased risk during the interval between pregnancies. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management protocols essential for effective interpregnancy care. Emphasis is placed on recent advances, emerging therapies, and evidence-based guidelines to inform clinical practice, with a focus on mechanism-driven interventions and practical implications for healthcare professionals.

Introduction

Maternal morbidity and mortality remain persistent public health concerns globally, with adverse outcomes often linked to factors present during the interpregnancy period. The interval between pregnancies defined as the time from the end of one pregnancy to the conception of the next offers a window of opportunity for targeted risk assessment and intervention. Interpregnancy risk stratification enables clinicians to individualize care, mitigate risks, and improve perinatal outcomes through systematic identification of at-risk women and tailored management strategies. This review explores the multidimensional aspects of interpregnancy risk stratification, integrating recent evidence and recommendations for clinical application.

Epidemiology / Disease Burden

Globally, short interpregnancy intervals (IPI), typically defined as less than 18 months, are associated with elevated risks of preterm birth, low birth weight, and maternal complications such as hypertensive disorders and gestational diabetes. Epidemiological data indicate that approximately 20–30% of women have an IPI of less than 18 months, with higher prevalence observed in low- and middle-income countries. Moreover, women with a history of adverse pregnancy outcomes, including preeclampsia or placental abruption, are at increased risk of recurrence in subsequent pregnancies. These epidemiological trends underscore the importance of structured interpregnancy risk assessment protocols.

Pathophysiology

The pathophysiological mechanisms underlying increased maternal and perinatal risks during short or closely spaced interpregnancy intervals include maternal nutritional depletion, incomplete uterine involution, and suboptimal recovery from physiological and metabolic stressors of pregnancy. Additionally, persistent inflammatory processes, unresolved comorbidities, and psychological stress may further exacerbate vulnerability to adverse outcomes. Understanding these mechanisms is essential for clinicians to implement targeted interventions that address the root causes of risk and prevent recurrence of complications.

Risk Factors

Key risk factors for adverse maternal outcomes during the interpregnancy period include: short (<18 months) or excessively long (>60 months) IPIs, advanced maternal age, pre-existing chronic diseases (e.g., hypertension, diabetes mellitus), obesity, previous pregnancy complications (e.g., preeclampsia, fetal growth restriction), substance use, inadequate prenatal care, and socioeconomic disadvantage. Recognizing and stratifying these risks allows for the development of individualized care plans and the allocation of resources to those most in need of intensive surveillance and intervention.

Clinical Features

Clinical manifestations of interpregnancy risk may be subtle or overt, ranging from asymptomatic women with a history of complications to those presenting with persistent hypertension, metabolic syndrome, or psychological distress. Early identification of clinical features such as poorly controlled chronic conditions, residual anemia, or unresolved postpartum complications is critical. A comprehensive clinical evaluation during the interpregnancy period serves as the foundation for risk stratification and subsequent management.

Diagnosis

Effective diagnosis of interpregnancy risk is predicated on a thorough review of the patient\'s obstetric, medical, and social history. Standardized risk assessment tools, such as the Interpregnancy Care Framework and the Maternal Early Warning Criteria, facilitate systematic evaluation. Laboratory investigations may include screening for anemia, thyroid dysfunction, diabetes, and infectious diseases, while imaging may be warranted for structural uterine anomalies. Psychosocial assessments are also recommended to identify mental health and support needs.

Treatment & Management

Management strategies for women identified as high-risk during the interpregnancy period are multifaceted and should be individualized. Interventions include optimizing control of chronic diseases, nutritional supplementation (e.g., folic acid, iron), counseling on optimal birth spacing, addressing modifiable lifestyle factors (e.g., smoking cessation, weight management), and ensuring timely postpartum follow-up. Multidisciplinary care coordination, involving obstetricians, primary care providers, nutritionists, and mental health professionals, is paramount in delivering comprehensive care. Contraceptive counseling and provision of effective contraception are integral components of interpregnancy management.

Recent Advances / Emerging Therapies

Recent advances in interpregnancy care include the development of digital health platforms for remote monitoring, predictive analytics for individualized risk profiling, and integration of social determinants of health into risk assessment tools. Emerging therapies focus on targeted interventions for metabolic syndrome, the use of anti-inflammatory agents in women with a history of preeclampsia, and the application of precision medicine approaches to optimize maternal recovery and future pregnancy outcomes. Ongoing research is evaluating novel biomarkers for early identification of at-risk women and the role of community health workers in bridging gaps in care.

Guideline Recommendations

Current guidelines from organizations such as the American College of Obstetricians and Gynecologists (ACOG), the World Health Organization (WHO), and the Royal College of Obstetricians and Gynaecologists (RCOG) emphasize the importance of interpregnancy risk stratification. Recommendations include routine postpartum visits for risk assessment, counseling on optimal IPI (ideally 18–24 months), individualized care plans for women with a history of adverse outcomes, and incorporation of social and behavioral determinants into clinical decision-making. Implementation of these guidelines is associated with improved maternal and perinatal outcomes.

Conclusion

Interpregnancy risk stratification represents a critical opportunity to enhance maternal health through proactive identification and management of women at increased risk. By integrating evidence-based assessment tools, multidisciplinary care, and guideline-driven interventions, healthcare professionals can mitigate the recurrence of adverse outcomes and promote optimal health in subsequent pregnancies. Ongoing research and innovation in risk assessment and intervention strategies will further strengthen the foundation for effective interpregnancy care.